S-1: another oral agent for patients with colorectal cancer
Mené sur 512 patients atteints d'un cancer colorectal métastatique, cet essai japonais de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement combinant S-1, oxaliplatine et bévacizumab avec celles d'une chimiothérapie mFOLFOX6 avec bévacizumab
In the past decade, efforts have been made worldwide to successfully develop agents and regimens that have meaningful clinical benefits for patients with metastatic colorectal cancer. For individuals who have access to the growing range of antineoplastic agents and who can receive several regimens and sequences over time, median survival has extended to more than 2 years. Although progress in colorectal cancer is lagging behind other disease sites, attempts have been made to define ...
The Lancet Oncology , commentaire, 2012